| Fund ID | 805-9220847822 |
| Fund type | Liquidity Fund |
| 3(c)(1) exclusion | Yes |
| 3(c)(7) exclusion | No |
| Master fund | Yes |
| Feeder fund | No |
| Fund of funds | No |
| Relies on exemption from registration | No |
| Annual audit | Yes |
| Prepared per GAAP | No |
| Sub-advised | No |
| Sales limited to qualified investors | Yes |
| % of assets independently valued | 0% |
| Owned by the adviser or related persons | 0% |
| Owned by funds of funds | 0% |
| Owned by non-U.S. persons | 0% |
| Fund | Type | Gross assets |
|---|---|---|
| 4bio Ventures III LP | Private Equity | $154M |
| 4bio Ventures II LP | Private Equity | $109.6M |
| 4bio Advanced Therapies Long Equity Fund | Liquidity | $440K |
4bio Advanced Therapies Fund Icav reports $439,683 in gross assets, among the top 97% of private funds by size.
The stated minimum investment is $200,000.
4bio Advanced Therapies Fund Icav is managed by 4bio Partners LLP.
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.